Here are the 424B prospectus supplements from SL Science Holding Limited (SLBT) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow SLBT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SLBT filings page.
SL Science Holding Limited is registering up to 1,040,000 Ordinary Shares for resale by PIPE investors after a six‑month lock‑up following the June 12, 2026 business combination with Horizon Space Acquisition II Corp. The company will not receive any proceeds from these sales.
The shares comprise 780,000 Ordinary Shares already held by investors and 260,000 Ordinary Shares issuable upon conversion of 780,000 series A preferred shares sold in a $10.00‑per‑Unit PIPE Financing. Ordinary Shares trade on Nasdaq under “SLBT,” last at $2.67 on August 12, 2026.
Chairman William Wang beneficially owns 333,832,129 Ordinary Shares, representing about 59.53% of voting power, making the company a Nasdaq “controlled company” able to rely on reduced board‑independence requirements. SL Science is an emerging growth, foreign private issuer developing pre‑clinical cell and gene therapies, with no FDA‑approved products and extensive scientific, regulatory, financing, concentration, IP, geopolitical and U.S./Taiwan regulatory risks highlighted.